An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2019

Primary Completion Date

February 27, 2022

Study Completion Date

September 30, 2024

Conditions
Gastric CancerCancer of the StomachStomach CancerGastroesophageal Junction
Interventions
BIOLOGICAL

Relatlimab + Nivolumab

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

DRUG

Paclitaxel

Specified dose on specified days

DRUG

Ramucirumab

Specified dose on specified days

Trial Locations (84)

1093

Local Institution, Buenos Aires

1199

Local Institution, CABA

1426

Local Institution, Buenos Aires

2145

Local Institution, Westmead

3000

Local Institution, Melbourne

3084

Local Institution, Heidelberg

3144

Local Institution, Malvern

5000

Local Institution, Córdoba

5024

Local Institution, Bedford Park

6150

Local Institution, Murdoch

8500

Local Institution, Viedma

13125

Local Institution, Berlin

14080

Local Institution, Mexico City

18103

Local Institution, Allentown

20133

Local Institution, Milan

20230

Local Institution, Aguascalientes

22763

Local Institution, Hamburg

24127

Local Institution, Bergamo

27599

Local Institution, Chapel Hill

28007

Local Institution, Madrid

28034

Local Institution, Madrid

28050

Local Institution, Madrid

28204

Local Institution, Charlotte

29029

Local Institution, Tuxtla Gutiérrez

30060

Local Institution, Marietta

30625

Local Institution, Hanover

33098

Local Institution, Paderborn

33176

Local Institution, Miami

33612

Local Institution, Tampa

35043

Local Institution, Marburg

36526

Local Institution, Daphne

37000

Local Institution, ZONA Centro. LEON

42100

Local Institution, Reggio Emilia

45147

Local Institution, Essen

46026

Local Institution, Valencia

50937

Local Institution, Cologne

55131

Local Institution, Mainz

57104

Local Institution, Sioux Falls

58102

Local Institution, Fargo

60488

Local Institution, Frankfurt am Main

63110

Local Institution, St Louis

65199

Local Institution, Wiesbaden

68167

Local Institution, Mannheim

72764

Local Institution, Reutlingen

79106

Local Institution, Freiburg im Breisgau

80045

Local Institution, Aurora

80131

Local Institution, Napoli

80228

Local Institution, Lakewood

90095

Local Institution, Los Angeles

90277

Local Institution, Redondo Beach

91054

Local Institution, Erlangen

92835

Local Institution, Fullerton

93105

Local Institution, Santa Barbara

93309

Local Institution, Bakersfield

97134

Local Institution, Mérida

98684

Local Institution, Vancouver

200347

Local Institution, Craiova

400015

Local Institution, Cluj-Napoca

407280

Local Institution, Floreşti

8330024

Local Institution, Santiago

02215

Local Institution, Boston

08009

Local Institution, New Brunswick

60430-230

Local Institution, Fortaleza

30130-090

Local Institution, Belo Horizonte

90035-903

Local Institution, Porto Alegre

14780-070

Local Institution, Barretos

17210-080

Local Institution, Jaú

22793-080

Local Institution, Rio de Janeiro

01246-000

Local Institution, São Paulo

B3H 2Y9

Local Institution, Halifax

L8V 5C2

Local Institution, Hamilton

K1H 8L6

Local Institution, Ottawa

M5B 1W8

Local Institution, Toronto

M5G 2M9

Local Institution, Toronto

H4J 1C5

Local Institution, Montreal

J1H 5N4

Local Institution, Sherbrooke

Unknown

Local Institution, Santiago

Local Institution, Medellín

07747

Local Institution, Jena

1649-035

Local Institution, Lisbon

4200-072

Local Institution, Porto

00935

Local Institution, Rio Piedras

022328

Local Institution, Bucharest

06006

Local Institution, Badajoz

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03704077 - An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter